NDAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
4/8 — Partial
Priority Review
ACIPHEX SPRINKLE (rabeprazole sodium) by Aytu BioPharma is (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine h 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric h , k atpase at the secretory surface of the gastric parietal cell. Approved for gastroesophageal reflux disease, heartburn, helicobacter pylori infection and 2 more indications. First approved in 2013.
Drug data last refreshed 19h ago
Mechanism of Action
(substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H , K ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded…
Indications (5)
Worked on ACIPHEX SPRINKLE at Aytu BioPharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.